Peter F Billingsley Selected Research

1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)

3/2022	Diagnostic performance and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled human malaria infection study in Equatorial Guinea.
2/2022	Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults.
1/2022	Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
10/2021	Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria Infection.
1/2021	Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection.
1/2021	Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults.
1/2021	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity.
12/2020	Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.
10/2020	Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection.
1/2020	A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter F Billingsley Research Topics

Disease

42	Malaria 03/2022 - 09/2008
32	Infections 03/2022 - 06/2002
11	Bites and Stings (Sting) 01/2020 - 10/2010
6	Parasitemia 02/2022 - 01/2016
3	Falciparum Malaria (Plasmodium falciparum Malaria) 12/2017 - 01/2010
1	Lymphadenopathy 11/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020
1	Communicable Diseases (Infectious Diseases) 01/2019
1	Sickle Cell Trait 01/2018
1	Myalgia 01/2017
1	Headache (Headaches) 01/2017
1	Fever (Fevers) 01/2017
1	Fatigue 01/2017
1	Parasitic Diseases (Parasitic Disease) 03/2013
1	Schistosomiasis (Bilharziasis) 03/2013
1	Vector Borne Diseases 09/2008
1	Dengue (Dengue Fever) 09/2008
1	Starvation 12/2002

Drug/Important Bio-Agent (IBA)

34	VaccinesIBA 02/2022 - 06/2002
24	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 03/2022 - 01/2013
11	Malaria VaccinesIBA 11/2020 - 10/2010
6	Pharmaceutical PreparationsIBA 01/2017 - 01/2013
5	Chloroquine (Aralen)FDA LinkGeneric 01/2021 - 10/2010
3	AntigensIBA 02/2022 - 03/2013
3	Proteins (Proteins, Gene)FDA Link 02/2022 - 12/2002
3	Antimalarials (Antimalarial Agents)IBA 01/2017 - 01/2013
2	AntibodiesIBA 02/2022 - 10/2020
1	Ribosomal DNA (rDNA)IBA 03/2022
1	Merozoite Surface Protein 1 (MSA1)IBA 02/2022
1	Pyrimethamine (Daraprim)FDA Link 01/2021
1	18S Ribosomal RNAIBA 01/2021
1	Saline SolutionIBA 01/2020
1	Complement System Proteins (Complement)IBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	Mefloquine (Lariam)FDA LinkGeneric 01/2017
1	Immune Sera (Antisera)IBA 04/2015
1	Peptides (Polypeptides)IBA 03/2013
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2002

Therapy/Procedure

3	Chemoprevention 01/2021 - 01/2017
3	Intradermal Injections 05/2015 - 01/2013
2	Mass Drug Administration 01/2017 - 12/2015
2	Injections 12/2015 - 12/2015
1	Intravenous Injections 01/2017
1	Intramuscular Injections 01/2014